MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1182/blood.2019001641

Медицинская библиотека · Blood · 2019

Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL.

Curran Kevin J, Margossian Steven P, Kernan Nancy A, Silverman Lewis B, Williams David A, Shukla Neerav, Kobos Rachel, Forlenza Christopher J, Steinherz Peter, Prockop Susan, Boulad Farid, Spitzer Barbara, Cancio Maria I, Boelens Jaap Jan, Kung Andrew L, Khakoo Yasmin, Szenes Victoria, Park Jae H, Sauter Craig S, Heller Glenn, Wang Xiuyan, Senechal Brigitte, O'Reilly Richard J, Riviere Isabelle, Sadelain Michel, Brentjens Renier J

Клиническое исследование I фазыСтатьяМногоцентровое исследованиеПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

Chimeric antigen receptor (CAR) T cells have demonstrated clinical benefit in patients with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). We undertook a multicenter clinical trial to determine toxicity, feasibility, and response for this therapy. A total of 25 pediatric/young adult patients (age, 1-22.5 years) with R/R B-ALL were treated with 19-28z CAR T cells. Conditioning chemotherapy included high-dose (3 g/m2) cyclophosphamide (HD-Cy) for 17 patients and low-dose (≤1.5 g/m2) cyclophosphamide (LD-Cy) for 8 patients. Fifteen patients had pretreatment minimal residual disease (MRD; <5% blasts in bone marrow), and 10 patients had pretreatment morphologic evidence of disease (≥5% blasts in bone marrow). All toxicities were reversible, including severe cytokine release syndrome in 16% (4 of 25) and severe neurotoxicity in 28% (7 of 25) of patients. Treated patients were assessed for response, and, among the evaluable patients (n = 24), response and peak CAR T-cell expansion were superior in the HD-Cy/MRD cohorts, as compared with the LD-Cy/morphologic cohorts without an increase in toxicity. Our data support the safety of CD19-specific CAR T-cell therapy for R/R B-ALL. Our data also suggest that dose intensity of conditioning chemotherapy and minimal pretreatment disease burden have a positive impact on response without a negative effect on toxicity. This trial was registered at www.clinicaltrials.gov as #NCT01860937.

Для цитирования: Curran Kevin J, Margossian Steven P, Kernan Nancy A, Silverman Lewis B, Williams David A, Shukla Neerav, Kobos Rachel, Forlenza Christopher J, Steinherz Peter, Prockop Susan, Boulad Farid, Spitzer Barbara, Cancio Maria I, Boelens Jaap Jan, Kung Andrew L, Khakoo Yasmin, Szenes Victoria, Park Jae H, Sauter Craig S, Heller Glenn, Wang Xiuyan, Senechal Brigitte, O'Reilly Richard J, Riviere Isabelle, Sadelain Michel, Brentjens Renier J. Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL.. Blood. 2019. DOI: 10.1182/blood.2019001641.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.